The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

Gearing was 14.3% at the end of March 2025 due to the seasonal effect of working capital variation ($3.4 billion) and normalized gearing was 11% excluding this effect.